US Biosimilar Uptake Could Be Driven By Outcomes-Based Contracts
This article was originally published in PharmAsia News
Executive Summary
Under risk-sharing agreement, a biosimilar's net price could be linked to achievement of efficacy results or adverse event rates similar to that of its reference product.